ClinicalTrials.gg
RecruitingNCT05951816Updated Jul 24, 2026

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

A Phase 1 interventional study of 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m. and 99mTc-Pyrophosphate in Systemic Amyloidosis, sponsored by University of Tennessee Graduate School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by University of Tennessee Graduate School of Medicine · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States — 23 open to participants now, 35 under way, 3 of them phase 3. Immunoglobulin Light-chain Amyloidosis · United States.

Planned enrollment
64th of 114
31 · median 38
Started
2023
with 3 others
Phase 1
36 of 151
5 open now
Primary completion
2026-12
later than 8 of 34 live
Registered
136th of 151
by date

Among the 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States, this one is the 64th largest by planned enrollment of the 114 interventional ones that give a count, is one of 4 that started in 2023, is one of 36 in phase 1, reaches primary completion later than 8 of the 34 other live ones, and was the 136th registered.

Immunoglobulin Light-chain Amyloidosis

239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.

Browse Immunoglobulin Light-chain Amyloidosis studies →

Open to participants now

23 of the 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States, or all of them as a file.
02

Study summary

This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL or ATTR-associated systemic amyloidosis, notably with cardiac involvement.

Read the detailed description

The University of Tennessee Graduate School of Medicine (UTGSM) is investigating 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for planar gamma scintigraphy (PGS), single photon emission computed tomography (SPECT) or SPECT with x-ray computed tomography (SPECT/CT) for the diagnosis of systemic amyloidosis, notably with cardiac involvement. Based on nonclinical data and clinical data of 124I-p5+14 from Study AMY1001, peptide p5+14 binds many types of human amyloid and is rapidly cleared from the central compartment. When radiolabeled with 99mTc, p5+14 may enable visualization of amyloid laden tissues and organs by SPECT/CT imaging or PGS. Thus, this study has been designed to evaluate the dosimetry and biodistribution of 99mTc-p5+14 in patients with systemic amyloidosis compared with the biodistribution in healthy volunteers.

03

Conditions studied

  • Systemic Amyloidosis

Keywords

  • Amyloidosis
  • p5+14
  • SPECT imaging
  • iodine-124-evuzamitide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PART 1

1) Understand the study procedures and agree to participate in the study by giving written ..

2) Be male or female >18 years of age. 3) Women of (WOCBP) (those who have not been surgically sterilized, are not [i.e., last menstrual period >2 years ago without pharmaceutical intervention], and women who are fertile) must have a negative pregnancy test prior within 24 h prior to infusion.

4) WOCBP who are not exclusively in same-sex relationships and male participants with female sexual partners who are WOCBP must agree to use adequate methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, for at least 2.5 days after injection of 99mTc-p5+14.

5) Be a healthy volunteer (n=3) or have a confirmed diagnosis of systemic amyloidosis (n=2) based on either a histologic confirmation with a containing deposits of apple-green birefringent, Congophilic material with aberrant organ-specific biomarkers indicating amyloid involvement, physical examination, or imaging study.

6) Healthy volunteers must also meet inclusion criteria for Part 3. PART 2

  1. Understand the study procedures and agree to participate in the study by giving written informed consent.
  2. Be male or female >18 years of age.
  3. WOCBP (those who have not been surgically sterilized, are not postmenopausal [i.e., last menstrual period >2 years ago without pharmaceutical intervention], and women who are fertile) must have a negative pregnancy test prior within 24 h prior to infusion.
  4. WOCBP who are not exclusively in same-sex relationships and male participants with female sexual partners who are WOCBP must agree to use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, for at least 2.5 days after injection of 99mTc-p5+14.
  5. Have one of the following:

    1. a confirmed diagnosis of systemic AL amyloidosis, based on either a histologic confirmation of a cardiac or extracardiac biopsy containing deposits of apple-green birefringent, Congophilic material AND imaging parameters (ECHO or CMR) indicative of cardiac involvement.
    2. a confirmed diagnosis of systemic ATTR amyloidosis, based on either a histologic confirmation of a cardiac biopsy containing deposits of apple-green birefringent, Congophilic material or extracardiac biopsy and imaging parameters (ECHO or CMR or 99mTc-PYP) indicative of cardiac involvement, with no evidence of abnormal serum free light chains.
  6. Have a diagnosis of cardiac amyloidosis within 4 years of screening, or longer if contemporaneous clinical data indicates the persistent presence of cardiac amyloidosis.

PART 3

  1. Understand the study procedures and agree to participate in the study by giving written informed consent.
  2. Be male or female >18 years of age.
  3. WOCBP (those who have not been surgically sterilized, are not postmenopausal [i.e., last menstrual period >2 years ago without pharmaceutical intervention], and women who are fertile) must have a negative pregnancy test prior within 24 h prior to infusion.
  4. WOCBP who are not exclusively in same-sex relationships and male participants with female sexual partners who are WOCBP must agree to use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, for at least 2.5 days after injection of 99mTc-p5+14.
  5. Be in good general health, as determined by no findings (including Type 2 diabetes mellitus) in the opinion of the Investigator from review of the medical history.
  6. Does not have a diagnosis of amyloidosis nor has a first- or second-degree relative (parent, sibling, child, aunt, uncle, niece, nephew) with confirmed or suspected familial amyloidosis.

PART 4

  1. Understand the study procedures and agree to participate in the study by giving written informed consent.
  2. Be male or female >18 years of age.
  3. Women of child-bearing potential (those who have not been surgically sterilized, are not postmenopausal [i.e., last menstrual period >2 years ago without pharmaceutical intervention], and women who are fertile) must have a negative pregnancy test prior within 24 h prior to infusion.
  4. WOCBP who are not exclusively in same-sex relationships and male participants with female sexual partners who are WOCBP must agree to use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, for at least 2.5 days after injection of 99mTc-p5+14.
  5. Has a confirmed diagnosis of systemic ATTR amyloidosis, based on either a histologic confirmation of a cardiac biopsy containing deposits of apple-green birefringent, Congophilic material or extracardiac biopsy and imaging parameters (ECHO or CMR), or abnormal serum biomarkers indicative of cardiac involvement, with no evidence of abnormal serum free light chains.
  6. Has a diagnosis of cardiac amyloidosis within 4 years of screening, or longer if contemporaneous clinical data indicates the persistent presence of cardiac amyloidosis.
  7. Has a negative 99mTc-PYP imaging study.

Exclusion criteria

Exclusion Criteria:

PARTS 1-4

  1. Due to annual dosimetry limitations, patients who have participated in another nuclear medicine amyloid imaging clinical trial protocol and received tracer injection in the last 6 months.
  2. Is pregnant or breast-feeding.
  3. Is mentally or legally incapacitated, has significant emotional problems at the time of the study, or has a history of psychosis.
  4. Receiving hemodialysis or peritoneal dialysis.
  5. Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol.
  6. Has any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject.
  7. Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within seven (7) days prior to 99mTc-p5+14 administration.
  8. Have previously received any dose of p5+14, in any form.
  9. Have a serum >2x the or 80 IU/L AND total > 1.5x the upper limit of normal or 1.8 mg/dL within the previous six months of enrollment.
  10. Have a serum ALT >2x the upper limit of normal or 64 IU/L AND total bilirubin > 1.5x the upper limit of normal or 1.8 mg/dL within the previous six months of enrollment.
  11. Have a , using Bazett's formula (QTcB) of >530 ms, measured within six months prior to enrollment, or assessed prior to injection.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Estimation of dosimetry for 99mTc-p5+14 and Biodistribution Of 99mtc-p5+14 In Healthy Subjects

    For dosimetry, healthy subjects (n=3) and patients with a confirmed diagnosis of AL (n=1) or ATTR amyloidosis (n=1) will be administered a single IV dose of up to 1 mg of 99mTc-p5+14 (\~20 mCi) by slow push (\~1 mL/5 sec.). Subjects will then undergo serial planar scintigraphic imaging at \~30 minutes, \~1 hour, \~2 hours, \~4 hours, \~6 hours, and \~24 hours post-injection. At the 4-hour time point, the subject will also undergo a single SPECT/CT scan to provide additional data for estimating dosimetry. Before injection of the radiotracer and at each imaging session, \~2 -3 mL of blood will be acquired to determine the whole blood radioactivity. An echo examination will also be performed. For physiological biodistribution, healthy volunteers (n=5) will undergo an echo examination, thereafter, they will be administered a single IV dose of 99mTc-p5+14 (20 mCi) and will undergo a planar image acquisition followed by SPECT/CT imaging at \~1 hour and \~3 hours post-injection.

    Drug: 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.

  • Experimental
    Biodistribution in patients with systemic AL or ATTR amlyoidosis

    On Day 1, patients with a confirmed diagnosis of systemic AL or ATTR (with or without a positive PyP scan) will be administered a single IV dose of up to 1 mg of 99mTc-p5+14 (\~20 mCi) by slow push (\~1 mL/5 sec.). At \~1 hour and \~3 hours post-injection, patients will undergo whole body planar imaging followed by abdominothoracic SPECT/CT imaging. Vital signs (blood pressure, respiration rate, temperature, and pulse) will be acquired before injection of the 99mTc-p5+14, and at \~3 hours post injection. ECG measurements will be made within 1 hour prior to, and within 15 minutes after, injection. On Day 3, patient will undergo a trans thoracic echo examination. On Day 4, patients will undergo Technescan™ 99mTc-PYP (20 mCi) planar and SPECT/CT imaging at \~1 hour and \~3 hours post-injection. Vital signs (blood pressure, respiration rate, temperature, and pulse) will be acquired before injection of the 99mTc-PYP, and at \~3 hours post injection. ECG measurements will be made as on Day 1.

    Drug: 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m. · Drug: 99mTc-Pyrophosphate

Interventions

  • Drug99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.

    Peptide p5+14 is a pan-amyloid reactive, synthetic 45 L-amino acid polypeptide with a net +12 positive charge that can bind two major components of all extracellular amyloid deposits: (i) hypersulfated heparan sulfate glycosaminoglycans (proteoglycans) and (ii) amyloid fibrils. The polypeptide, labeled with iodine-124, has been shown (study AMY1001) to bind amyloid in all organs including the heart. This study will evaluate a Tc-99m-labeled version of the peptide for gamma imaging.

  • Drug99mTc-Pyrophosphate

    99mTc-PYP is an FDA-approved, commercially available bone-seeking radiotracer used routinely in nuclear medicine. 99mTC-PYP imaging is used clinically for the diagnosis of cardiac ATTR amyloidosis.

    Also known as: 99mTc-PYP

06

What researchers measure

Primary outcomes

  1. Whole body effective dosimetry measurement

    Whole body effective radiation dose assessed from analysis of organ-specific radioactivity uptake in planar and SPECT images.

    Time frame: From enrollment to the end of study is 8 days

Secondary outcomes

  1. Measure cardiac uptake of 99mTc-p5+14 radioactivity from planar and SPECT/CT images in comparison to 99mTc-PYP uptake

    Measurement of 99mTc-p5+14 uptake in the heart of healthy volunteers and patients with systemic AL or ATTR amyloidosis and comparison with contemporaneous 99mTc-PYP cardiac radioactivity.

    Time frame: From enrollment to the end of study is 8 days

  2. Measure uptake of 99mTc-p5+14 radioactivity in extracardiac tissues from planar and SPECT/CT images

    Measurement of 99mTc-p5+14 radioactivity in abdominothoracic organs of healthy volunteers and patients with systemic AL or ATTR amyloidosis from planar and SPECT/CT images.

    Time frame: From enrollment to the end of study is 8 days

Other outcomes

  1. Compare planar and SPECT imaging of 99mTc-p5+14 for the detection of cardiac amyloid

    To compare the quantitative cardiac uptake of 99mTc-p5+14 and 99mTc-PyP in patients with systemic ATTR amyloidosis imaged by planar gamma scitigraphic and SPECT/CT imaging acquired at 1-hour and 3-hour post-injection.

    Time frame: From enrollment to the end of study is 8 days

07

Study locations

1 of 1 sites recruiting
  • University of Tennessee Graduate School of Medicine
    Knoxville, Tennessee 37920, United States
    Recruiting
    • Emily B Martin, PhD · Contactemartin@utmck.edu · 865-305-9533
    • Jonathan S Wall, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 19, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05951816
Lead sponsor
University of Tennessee Graduate School of Medicine
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Sep 18, 2023
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 24, 2026

Study contacts

Emily B Martin, PhD
Contact
emartin@utmck.edu
865-305-9533
Jonathan S Wall, PhD
principal investigator · University of Tennessee Graduate School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion